End Points for Testing Influenza Antiviral Treatments for Patients at High Risk of Severe and Life‐Threatening Disease
Authors:
Open Access
- 1 June 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 201 (11) , 1654-1662
Abstract
Influenza infection results in substantial morbidity and mortality in hospitalized patients, including those who are immunocompromised or pregnant. Antiviral therapy likely provides considerable benefit to these patients, but few studies have been successfully conducted in these high-risk populations, and no drugs are specifically licensed for treating these subgroups. One of the key challenges facing novel antiviral drug development for influenza is determining the appropriate efficacy end points that would enable rapid regulatory approval for drug use in seriously ill patients, for whom risk-benefit assessments differ from those with uncomplicated illness. All available antiviral drugs currently affect viral replication, and respiratory tract viral titers correlate with both symptoms and measures of host inflammatory responses, including cytokine and chemokine expression that are likely responsible for many of the clinical symptoms. Consequently, we outline the evidence to support the use of primary virological end points in studies of antiviral agents involving patients who are hospitalized with severe influenza or those who are at high risk of severe and life-threatening disease.Keywords
This publication has 52 references indexed in Scilit:
- Animal models for the study of influenza pathogenesis and therapyAntiviral Research, 2009
- Influenza virus shedding—Excretion patterns and effects of antiviral treatmentJournal of Clinical Virology, 2009
- Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United StatesJAMA, 2009
- Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case seriesThe Lancet, 2008
- Outcome of Influenza Infection Managed With Oseltamivir in Lung Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2008
- Impact of Rapid Diagnosis on Management of Adults Hospitalized With InfluenzaArchives of internal medicine (1960), 2007
- Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United StatesJAMA, 2006
- Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concernThe Lancet, 2005
- Resistant influenza A viruses in children treated with oseltamivir: descriptive studyThe Lancet, 2004
- Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1?5 yearsEuropean Journal of Clinical Pharmacology, 2003